Latest Media Releases (Page 12) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Next Science - Trading Halt (ASX:NXS)

The securities of Next Science Limited (‘NXS’) will be placed in trading halt at the request of NXS, pending it releasing an announcement. Unless ASX decides otherwise, the securities wi...read more

Austco Healthcare FY23 Results Media Release (ASX:AHC)

-- Revenue from customers up 17% to $42.0 million -- Software and SMA revenues up 65% to $8.5 million -- Gross Margins increased to 53.4% compared to 52.5% in pcp -- Research and Development inve...read more

Austco Healthcare - Appendix 4G and Corporate Governance Statement (ASX:AHC)

To view the appendix, download the attached PDF.

Austco Healthcare - Appendix 4E & FY23 Financial Statements (ASX:AHC)

To view the appendix, download the attached PDF.

Radiopharm Theranostics - TerThera Terbium-161 isotope supply agreement expanded (ASX:RAD)

SYDNEY, August 24, 2023 - Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic us...read more

Austco Healthcare awarded $2.6M contract (ASX:AHC)

Azure Healthcare Limited’s (ASX: AHC) wholly owned subsidiary Austco Marketing & Service (Asia) Pte Ltd has secured a A$2.6M contract to supply its Tacera Nurse Call platform to Mount Eliz...read more

Chimeric Therapeutics - Positive data - CHM 0301 next-gen armoured NK cell platform (ASX:CHM)

Sydney, Australia, 15 August 2023: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce positive in vitr...read more

INOVIQ - EXO-OC Program Completes Serum Equivalence Study (ASX:IIQ)

Serum equivalence study confirms EXO-NET isolates extracellular vesicles (EVs) from both plasma and serum samples- enables access to large ovarian cancer serum biobanks for further research ...read more

Next Science - Potential Anti-Inflammatory Benefit For XPERIENCE (ASX:NXS)

Highlights: Dr Andrew B. Wickline, MD, FAAOS has released the findings of a pilot study which demonstrated 54% lower inflammation within 14 days compared to the common reference ...read more

Next Science - Investor Presentation (ASX:NXS)

To view the Investor Presentation, download the attached PDF.

Immutep receives positive scientific advice from EMA (ASX:IMM)

SYDNEY, AUSTRALIA – 1 August 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel ...read more

INOVIQ - INOVIQ Investor Briefing (ASX:IIQ)

To view the Investor Briefing, download the attached PDF.

Immutep - Efti clinical data to be presented at ESMO Congress 2023 (ASX:IMM)

-- Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® (pembrolizumab) -- Two additional posters on investi...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

Highlights: -- Orphan Drug Designation granted by FDA for Ga68-Trivehexin (RAD 301) -- Successful completion of pre-Investigational New Drug (IND) meeting with the FDA concerning F18-pivalate (R...read more

Viewing: 166 - 180 of 200 Previous | Next